12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Summary

This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.

Timeline

Start

2017-06-20

Primary completion

2018-07-27

Completion

2018-07-27

Drugs

Indications